National Bank of Canada’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

National Bank of Canada’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-250	Closed	-$168	–	3104
2024 Q2	$168	Hold	250	–	–	﹤0.01%	2612
2024 Q1	$150	Buy	250 +106	+74%	+$65	﹤0.01%	2649
2023 Q4	$88	Hold	144	–	–	﹤0.01%	2663
2023 Q3	$91	Hold	144	–	–	﹤0.01%	2725
2023 Q2	$473	Sell	144 -2	-1%	-$6	﹤0.01%	2620
2023 Q1	$1.33K	Hold	146	–	–	﹤0.01%	2492
2022 Q4	$1.71K	Hold	146	–	–	﹤0.01%	2518
2022 Q3	$3K	Hold	146	–	–	﹤0.01%	2472
2022 Q2	$4K	Hold	146	–	–	﹤0.01%	2501
2022 Q1	$7K	Sell	146 -30	-17%	-$1.48K	﹤0.01%	2489
2021 Q4	$12K	Buy	+176	New	+$14.8K	﹤0.01%	2312

National Bank of Canada's VBIV Position: Q3 2024 in Review

National Bank of Canada sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2024, closing a stake of 250 shares — an estimated $168 sold.

National Bank of Canada first reported a position in VBIV in Q4 2021 and held it in 11 quarters. The position peaked at $12K in Q4 2021. 1 fund tracked by Wall St. Rank holds VBIV as of Q3 2024.

National Bank of Canada reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2024 after selling out during the quarter.
National Bank of Canada sold 250 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2024, an estimated $168.
National Bank of Canada first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2021 and held it in 11 quarters.
National Bank of Canada's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $12K in Q4 2021.
1 fund tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2024.

Based on National Bank of Canada's 13F filing for Q3 2024, filed 12 Nov 2024.